Business Combination, Consideration, Liability, Deferred Consideration Payable

No definition available.

Name:	ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the amount of outstanding stock appreciation rights liability.

+ References

No definition available.

+ Details

Name:	ptct_StockAppreciationRightsLiabilityOutstanding
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (aa)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563

+ Details

Name:	us-gaap_AvailableForSaleSecuritiesDebtSecurities
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph b
-URI http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740

+ Details

Name:	us-gaap_EquitySecuritiesFvNi
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

+ Details

Name:	us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=ptct_BioElectronMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Fair value of financial instruments and investments - Schedule of financial assets and liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Aug. 23, 2018
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Marketable securities	$ 398,535	$ 58,088
Contingent consideration payable	356,300	310,240
Fair Value, Measurements, Recurring \| Total
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Marketable securities	398,535	58,088
Equity Investment	6,194
Stock appreciation rights liability	3,186	3,814
Deferred consideration payable	40,000	37,700
Contingent consideration payable		257,040
Contingent consideration payable- net sales milestones and royalties		53,200
Fair Value, Measurements, Recurring \| Quoted prices in active markets for identical assets (level 1)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Marketable securities	0	0
Equity Investment	6,194
Stock appreciation rights liability	0	0
Deferred consideration payable	0	0
Contingent consideration payable		0
Contingent consideration payable- net sales milestones and royalties		0
Fair Value, Measurements, Recurring \| Significant other observable inputs (level 2)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Marketable securities	398,535	58,088
Equity Investment	0
Stock appreciation rights liability	0	0
Deferred consideration payable	40,000	37,700
Contingent consideration payable		0
Contingent consideration payable- net sales milestones and royalties		0
Fair Value, Measurements, Recurring \| Significant unobservable inputs (level 3)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Marketable securities	0	0
Equity Investment	0
Stock appreciation rights liability	3,186	3,814
Deferred consideration payable	0	0
Contingent consideration payable		257,040
Agilis
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Deferred consideration payable			$ 38,100
Agilis \| Significant unobservable inputs (level 3)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration payable- net sales milestones and royalties	65,800
Agilis \| Fair Value, Measurements, Recurring \| Total
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration payable	290,500
Contingent consideration payable- net sales milestones and royalties	65,800
Agilis \| Fair Value, Measurements, Recurring \| Quoted prices in active markets for identical assets (level 1)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration payable	0
Contingent consideration payable- net sales milestones and royalties	0
Agilis \| Fair Value, Measurements, Recurring \| Significant other observable inputs (level 2)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration payable	0
Contingent consideration payable- net sales milestones and royalties	0
Agilis \| Fair Value, Measurements, Recurring \| Significant unobservable inputs (level 3)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration payable	$ 290,500
BioElectron \| Fair Value, Measurements, Recurring \| Significant unobservable inputs (level 3)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration payable- net sales milestones and royalties		$ 53,200